Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

301.12

Mkt cap

6.6B

Volume

293K

High

308.65

P/E Ratio

-12.32

52-wk high

368.29

Low

295.02

Div yield

N/A

52-wk low

168.25

Wall Street analysts have set an average price target for Madrigal Pharmaceuticals (MDGL) that suggests a potential upside of 26.4%. This optimism is supported by positive trends in earnings estimate revisions, which could lead to a stock price increase.

Portfolio Pulse from

November 18, 2024 | 4:15 pm

The article suggests investing $1,000 in a promising biotech stock, potentially Madrigal Pharmaceuticals (MDGL), and holding it for at least five years due to its bright future.

Portfolio Pulse from

November 10, 2024 | 2:45 pm

Madrigal Pharmaceuticals (MDGL) is highlighted as a strong momentum stock, suggesting it could be a top pick for momentum investors.

Portfolio Pulse from

November 07, 2024 | 6:15 pm

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) will participate in fireside chats at three upcoming investor conferences, potentially increasing investor interest and visibility.

Portfolio Pulse from

November 06, 2024 | 1:15 pm

Madrigal Pharmaceuticals shares rose following UBS's decision to maintain a Buy rating and increase the price target from $411 to $441.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 7:25 pm

UBS analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals and increased the price target from $411 to $441.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:27 pm

Madrigal Pharmaceuticals shares rose following the release of their Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 2:11 pm

The article highlights significant pre-market movements in healthcare stocks on Thursday. Notable gainers include Autonomix Medical, Tenon Medical, and Aerovate Therapeutics, while Matinas BioPharma and Equillium are among the biggest losers. Several companies reported Q3 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:10 pm

Several healthcare stocks experienced significant price movements in Thursday's pre-market session. Notable gainers include Autonomix Medical, Tenon Medical, and Alphatec Holdings, while Matinas BioPharma and Equillium saw substantial declines.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:09 pm

Madrigal Pharmaceuticals reported better-than-expected Q3 2024 results, with a GAAP EPS of $(4.92) beating the estimate of $(6.92) and sales of $62.175 million surpassing the $33.656 million estimate.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:05 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.